Type 2 Diabetes

How can adolescent body mass index influence T2DM risk later in adulthood? A new study offers insight. 

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

The FDA has approved Johnson & Johnson’s canagliflozin (INVOKANA) for patients with type 2 diabetes who have established cardiovascular disease in order to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

Highlights include: "Artificial pancreas" improves glucose control; T1DM often misdiagnosed as T2DM; and a genetic connection for “type 1.5 diabetes.” 

New data suggest hepatitis C infection, but not hepatitis B infection, increases the prevalence of diabetes in patients who undergo kidney transplants.

Three new studies in diabetes research highlight the importance of whole grains and gluten in T2DM and T1DM risk. 

A comparative study found that online prevention programs are just as effective and have higher participation rates compared to in-person programs.

Lucia Novak discusses the importance of testing for cardiovascular outcomes of diabetes treatments and compares the cardiovascular effects of several diabetes drugs.

Lucia Novak, a diabetes care specialist, discusses some of the gaps that remain in diabetes management and what providers can do to help bridge those.